WO2009098029A2 - Article destiné à panser une plaie - Google Patents

Article destiné à panser une plaie Download PDF

Info

Publication number
WO2009098029A2
WO2009098029A2 PCT/EP2009/000716 EP2009000716W WO2009098029A2 WO 2009098029 A2 WO2009098029 A2 WO 2009098029A2 EP 2009000716 W EP2009000716 W EP 2009000716W WO 2009098029 A2 WO2009098029 A2 WO 2009098029A2
Authority
WO
WIPO (PCT)
Prior art keywords
wound
ellagic acid
care article
wound care
wound dressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/000716
Other languages
German (de)
English (en)
Other versions
WO2009098029A3 (fr
Inventor
Volker Achterberg
Andrea Heuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of WO2009098029A2 publication Critical patent/WO2009098029A2/fr
Publication of WO2009098029A3 publication Critical patent/WO2009098029A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules

Definitions

  • the present invention relates to wound dressings or wound care articles capable of promoting or accelerating the coagulation of blood.
  • Known wound care articles based on natural or synthetic materials are designed to absorb escaping blood and wound fluid.
  • the secretion and blood is bound in its entirety and thus removed from the wound surface.
  • the hemostasis is then initiated by the body's own processes.
  • Wound care articles include wound dressings (especially patches), swabs, cotton wool and tampons made from natural fibers or man-made fibers.
  • a very modern type of wound care is the covering of wounds by thin sheets or gels of polymeric materials, e.g. Polyurethane foils, foams or hydrogels.
  • a patch is usually composed of a wound dressing which contacts the wound, and of a carrier material, which usually in the middle of the wound dressing and around it carries an adhesive layer built.
  • a carrier material which usually in the middle of the wound dressing and around it carries an adhesive layer built.
  • B dirt, germs or moisture, reached.
  • the shape and material are adjusted accordingly. So there are already a variety of shape variants for use on fingers, joints, feet, for burns or injection sites and the like.
  • wound dressings made of materials with special properties which have a positive influence on certain wound healing processes are increasingly gaining in importance. This can be achieved by the wound dressing material possessing these properties per se or by doping with application-specific active substances.
  • Materials or active substances used in wound plasters are, for example, alginates or infection-reducing silver-doped / -containing wound dressings. Also described are materials for wound dressings which are intended to have hemostatic effects by means of various mechanisms (MC Neuffer et al., Military Medicine 169 (2004), 716-720).
  • These hemostatic materials have several disadvantages, such as high cost of substances of natural (especially animal) origin (such as collagen, chitosan, thrombin / fibrinogen), risk of thermal damage (such as in zeolites) or lack of leaching effect from the capillary (such as polysaccharide particles).
  • Wound care products such as tampons, cotton wool or swabs are usually not used for healing support, but are only brought into contact with the wound for a short time in order to absorb wound secretions until the bleeding stops.
  • the injuries to be treated are bleeding wounds.
  • the coverage of the area of injury involves the difficulty that with a normal patch or swab the bleeding can not be stopped fast enough and much effluent has to be absorbed by the wound care article.
  • the absorption capacity of the wound care article is exhausted-especially in the case of patches, the absorption capacity is very low, unlike that of the right dressings or swabs-it can happen that blood or wound secretion passes through the wound care article, in particular the backing material of a plaster and, in the worst case, the patch from the skin is lifted. It would therefore be advantageous to accelerate the coagulation process in order to avoid excessive bleeding or secretion.
  • the wound care articles should be suitable as a wound dressing, in particular for use in patches.
  • the present invention therefore relates to wound care articles, in particular wound dressing or swabs, which have an effective concentration of ellagic acid, and patches which contain an ellagic acid-containing wound dressing of the aforementioned type.
  • Ellagic acid is a polyphenol with a molecular weight of 338.2 g / mol and has the following structure:
  • ellagic acid is found in significant concentrations of up to 1% in many plants and woody plants. These include raspberries, pomegranates, strawberries, blackberries, walnuts and many other fruits and nuts. Together with gallic acid, it is also found in rose plants. By acid hydrolysis, the ellagtannin decomposes, inter alia, in ellagic acid. In water, ellagic acid is only sparingly soluble, but it dissolves in ethanol, dilute alkalis, and pyridine.
  • Ellagic acid is also known as a component of diagnostics for the investigation of the intrinsic pathway of blood coagulation. It promotes fibrin formation, assuming that ellagic acid is responsible for surface activation. (T.Exner & K. A. Rickard, Thromb. Res. 26 (1982), 83-89; A. Girolami et al., Blood 27 (1966), 93-102).
  • the poor solubility of the ellagic acid causes the impregnation or doping to be carried out for producing a wound dressing according to the invention with suspensions of ellagic acid. It is advantageous to treat the suspensions with ultrasound before being applied to the wound dressing in order to minimize the mean particle size.
  • the sources of ellagic acid are advantageously and preferably natural sources.
  • the ellagic acid was prepared from natural sources, in particular from purified extracts of plant parts containing ellagic acid, in particular from fruits.
  • ellagic acid obtained from pomegranates is particularly advantageous for the hemostatic effect.
  • the coagulation process is accelerated compared to pure, synthetically produced ellagic acid.
  • Ellagic acid is characterized by a very poor solubility in water, so that the effect depends very much on the free surface.
  • wound care products in which the doping was carried out with suspensions having a mean particle size of less than or equal to 3 .mu.m, especially an average particle size of less than or equal to 1 .mu.m have proven to be extremely effective.
  • a tissue or fleece or a shaped body pressed from cotton wool is used as the wound care article according to the invention.
  • an open-pore material in particular a sponge (for example polyurethane foam) instead of a woven or non-woven fabric.
  • the wound care article consists of an absorbent, in particular swellable, material.
  • the content of ellagic acid in voluminous wound care articles should be between 1 ⁇ g to 10 mg per gram of substrate, in particular between 80 ⁇ g / g and 320 ⁇ g / g.
  • patches for covering wounds are also present, which have a carrier material on which a wound dressing doped with ellagic acid is fixed.
  • the wound dressing does not completely cover the carrier material, so that the part of the carrier material not covered by the wound dressing, as usual with patches, can be used as an adhesive surface for fixing the patch to the skin.
  • the wound dressing does not cover more than 90%, in particular not more than 75% and especially not more than 45% of the area of the wearer.
  • the content of ellagic acid on the wound dressing should be between 0.01 ⁇ g and 100 ⁇ g per cm 2 , advantageously between 0.4 ⁇ g and 1.6 ⁇ g per cm 2 .
  • a particularly advantageous embodiment of a wound care article according to the invention for wound care comprises a carrier material which is at least partially coated with a polymeric wound dressing which is applied to the wound to be covered.
  • the wound dressing is a film-like sheet, which can advantageously be self-adhesive.
  • hydrocolloids or hydrogels For the purposes of the invention, it is for such an embodiment to apply a wound dressing of hydrocolloids or hydrogels to the carrier material.
  • the preferred hydrocolloid or hydrogel matrix preferably extends over the entire surface of the carrier material and, because of its self-adhesive property, also serves for fixation on the skin.
  • the ellagic acid in particulate form is incorporated into the polymeric wound dressing as a monolithic system.
  • the particles ellagic acid incorporated into the polymer systems on the wound-side surface are used for efficacy development.
  • the polymeric wound dressing the ellagic acid is released into the wound.
  • Hydrogel matrices as a possible polymeric wound dressing which are suitable for doping with ellagic acid, are exemplified as polyacrylic acid / sea algae extract base systems and described in DE 102 608 73.
  • an appropriate anhydrous alcohol-based gel matrix may also be used.
  • Such self-adhesive wound secretions or blood-collecting matrix systems by crosslinking polyacrylic acid / polyvinylpyrrolidone are described by way of example in DE 10142918.
  • the ellagic acid or its suspension is incorporated in a matrix system of polyacrylic acid / polyvinyl alcohol, which forms gel structures and, associated therewith, also self-adhesive properties only through the uptake of wound secretion or blood.
  • a matrix system of polyacrylic acid / polyvinyl alcohol which forms gel structures and, associated therewith, also self-adhesive properties only through the uptake of wound secretion or blood.
  • Corresponding moist adhesive films for wound care are described by way of example in DE 10224420.
  • a monolithic silicone matrix in which the absorbency of the matrix system for wound exudate can be adjusted by the incorporation of powdery gelling agents, such as, for example, polyacrylic acids or celluloses can be used as the base matrix for ellagic acid for wound care.
  • powdery gelling agents such as, for example, polyacrylic acids or celluloses
  • Such type pressure sensitive adhesive systems based on silicone gels are described by way of example in DE 10114382.
  • Analogous self-adhesive monolithic matrix systems can also be prepared by appropriate compounding with other hydrophobic polymers.
  • DE 102 12 864 describes, for example, a mixing system for solubilization of pharmaceutical active ingredients with which the water absorption capacity of the polymer matrix for wound care can be adjusted.
  • these systems of originally highly hydrophobic polymers, e.g. Polyisobutylene or block polymers such as styrene / isoprene / styrene, the water absorption capacity is influenced by the incorporation of micronized cellulose or other powdery hydrocolloids.
  • These systems are therefore also well suited for the incorporation according to the invention of ellagic dispersions or pulverized ellagic acid.
  • Suitable wound treatment products of polyurethane base for the inventive doping with ellagic acid are, for example HANSAPLAST ® Active Gel Strip or HANSAPLASf 8 bubbles patch.
  • the polymer system - containing the monomers and optionally other constituents in the case of reactive resin systems or containing dissolved or swollen polymers in the case of solvent-containing systems - surface on a release liner (release paper or film) applied in the final embodiment, the carrier material, ie in the final product to be transferred.
  • the carrier material ie in the final product to be transferred.
  • hotmelt systems that manage without solvent.
  • the above-described concentration can be achieved by using in the preparation of solvent-containing systems, such as e.g. Polyisobutylene or block polymers, but also a matrix system of polyacrylic acid / polyvinyl alcohol, the drying process of the final matrix system is delayed.
  • solvent-containing systems such as e.g. Polyisobutylene or block polymers
  • a matrix system of polyacrylic acid / polyvinyl alcohol the drying process of the final matrix system is delayed.
  • hot-melt adhesive matrices or heat-compounded matrices as a polymeric wound dressing, the cooling and, associated therewith, the increase in viscosity can be delayed in time.
  • the latter approach is e.g. also advantageous in the production of hydrogels.
  • ellagic acid As a spray plaster.
  • Spray patches are already known, eg HANSAPLAST ® spray patches.
  • the film-forming polymer is dissolved in a solvent applied directly to the wound and by evaporation of the solvent, the wound-covering film forms.
  • the ellagic acid can be dispersed directly before use by shaking the aerosol can in solvents such as ethanol and then applied directly to the wound and unfold the coagulation-accelerating effect.
  • the forming polymer film serves only to protect the wound from external physical influences (eg scrubbing, scratching, etc.) and the penetration of germs.
  • ellagic acid-containing polymer solutions as above as a spray, but as a pure solution by means of a suitable applicator such.
  • a special form is ointments, emulsions or gels containing ellagic acid or ellagic acid suspension, which are applied to the wound to be treated and form a polymer film there.
  • the polymer film forms within a drying process to form a self-contained wound-covering film. The release of the ellagic acid particles takes place from the film surface contacting the wound.
  • a technologically particularly mature application form of a base matrix for the above can be found in DE102006049929.
  • a film-forming gel matrix for use in wound treatment based on a mixture of a hydrophobic polyisobutylene / vaseline gel and a hydrophilic polyacrylic acid / water gel. example 1
  • ellagic acid Two different qualities of ellagic acid were tested for efficacy in two in vitro haemostatic assays. These were: a) ellagic acid from pomegranate extract with ⁇ 90% ellagic acid (from Wagott) b) ellagic acid, pure, ⁇ 96% (synthetic, from Fluka, 45140)
  • the powdery substances were suspended in phosphate buffered saline (PBS) at a concentration of 3.4 mg / ml (10 mmol / l) and used as a finely dispersed suspension either directly or after sonication (ultrasonic bath, in ice for 30 min). Thereafter, the suspensions were diluted 1: 100 with PBS to a concentration of 34 ⁇ g / ml (0.1 mmol / L) of ellagic acid.
  • PBS phosphate buffered saline
  • the test is carried out in accordance with ISO 10993-4, part B3, with citrated blood (CB).
  • Ellagic acid suspension (a ⁇ ) from pomegranate extract causes in this test, even at a final concentration of about 0.1 mmol / l, a significant shortening of the clotting time compared to the control CB + PBS ( Figure 1).
  • the pure synthetically produced ellagic acid (bi) resulted g, however, only a very small reduction in the clotting time.
  • Ultrasound treatment of the stock solutions (a 2 and b 2 ) additionally resulted in a shortening of the clotting time compared to untreated stock solutions (ai and b ⁇ . This was more pronounced when using a 2 than when b 2 was used .
  • Thromboelastography is a global assay for quantifying blood clotting of whole blood (J.A. Caprini et al., 'Perspectives on thromboelastography', Semin Thromb, Hemost 21 (Suppl. 4, 1995), 91-93).
  • the main measurement parameter is the clotting time: the time to fibrin clot formation. Hemostatic substances shorten the fibrin formation time.
  • Example 2 Doping of a wound dressing material with ellagic acid
  • a standard polypropylene wound dressing was punched out (20 mm diameter, mass 15.5 mg) and doped with ellagic acid suspension as follows:
  • Figure 4 shows the result of Example 2 (treatment by autoclaving (A), clotting assay) of stock solution a 2 on PP nonwoven (V + a 2 + A) and undoped PP nonwoven (V + A) over undoped PP Fleece with PBS (V + PBS + A).
  • V sample PP fleece without autoclaving
  • CB blood sample without additive

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des pansements ou des articles destinés à panser une plaie, pouvant faciliter ou accélérer la coagulation sanguine.
PCT/EP2009/000716 2008-02-06 2009-02-04 Article destiné à panser une plaie Ceased WO2009098029A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008008537.5 2008-02-06
DE200810008537 DE102008008537A1 (de) 2008-02-06 2008-02-06 Wundversorgungsartikel

Publications (2)

Publication Number Publication Date
WO2009098029A2 true WO2009098029A2 (fr) 2009-08-13
WO2009098029A3 WO2009098029A3 (fr) 2010-07-01

Family

ID=40627612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000716 Ceased WO2009098029A2 (fr) 2008-02-06 2009-02-04 Article destiné à panser une plaie

Country Status (2)

Country Link
DE (1) DE102008008537A1 (fr)
WO (1) WO2009098029A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172747A1 (fr) 2024-02-14 2025-08-21 Ethicon, Inc. Pâte fluide à complexe d'acide ellagique-nickel et ses utilisations pour activer la coagulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444572B2 (ja) * 2019-09-24 2024-03-06 シスメックス株式会社 活性化部分トロンボプラスチン時間測定用試薬及び試薬キット、並びにエラグ酸化合物の沈殿を抑制する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5838208A (ja) * 1981-08-29 1983-03-05 Sunstar Inc タンニン配合口腔適用組成物
EP0525035B1 (fr) * 1990-04-17 1996-07-03 Analytical Control Systems, Inc. Titrages et reactifs de coagulation
KR950702909A (ko) * 1992-08-17 1995-08-23 패트릭 디. 쿠갠 입자 결합제
US6340411B1 (en) * 1992-08-17 2002-01-22 Weyerhaeuser Company Fibrous product containing densifying agent
US6066312A (en) * 1996-07-16 2000-05-23 Lion Corporation Topical composition for application to the skin containing an ellagic acid-based compound or salt thereof
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
US20040077538A1 (en) * 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
DE10037983B4 (de) * 2000-08-03 2006-04-13 Stefan Zikeli Polymerzusammensetzung und daraus hergestellter Formkörper mit einem Gehalt an Alkaloid
JP4073231B2 (ja) * 2002-03-28 2008-04-09 久光製薬株式会社 シ−ト状貼付剤
JP4398158B2 (ja) * 2002-10-03 2010-01-13 久光製薬株式会社 貼付剤
EP1635850B1 (fr) * 2003-06-20 2008-08-13 Johnson & Johnson Medical Ltd. Antimicrobien a l'argent
GB2402880B (en) * 2003-06-20 2008-01-23 Johnson & Johnson Medical Ltd Antimicrobial compositions comprising silver
US20050089551A1 (en) * 2003-10-22 2005-04-28 Recupero Elizabeth A. Clotting agent-containing window dressing
EA009669B1 (ru) * 2004-01-01 2008-02-28 Панацея Биотек Лтд. Фармацевтические композиции, содержащие экстракт euphorbia prostrata
WO2007004229A2 (fr) * 2005-07-06 2007-01-11 Rimonest Ltd. Methodes d'utilisation de fractions de grenades pour reparer la peau
EP1951260A4 (fr) * 2005-10-21 2009-11-11 Bezwada Biomedical Llc Composés phénoliques fonctionnalisés et dispositifs absorbables fabriqués à partir desdits composés
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172747A1 (fr) 2024-02-14 2025-08-21 Ethicon, Inc. Pâte fluide à complexe d'acide ellagique-nickel et ses utilisations pour activer la coagulation

Also Published As

Publication number Publication date
DE102008008537A1 (de) 2009-08-13
WO2009098029A3 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
DE3687088T2 (de) Blutstillendes heftpflaster.
EP2340053B1 (fr) Dispositif de soins des plaies
Hassiba et al. Review of recent research on biomedical applications of electrospun polymer nanofibers for improved wound healing
Pedram Rad et al. Preparation and characterization of Calendula officinalis-loaded PCL/gum arabic nanocomposite scaffolds for wound healing applications
CN107693835B (zh) 一种聚乙烯醇/胶原蛋白/季铵化壳聚糖静电纺丝复合纤维膜及其制备方法
DE69623801T2 (de) Wasserlöslicher film
DE69817574T2 (de) Herstellungsmethode für ein faserfreies, poröses material
DE68907362T2 (de) Hydrophile Schaumzusammensetzungen.
DE69032125T2 (de) Gelwundverbandszusammensetzungen und verfahren zu deren gebrauch
DE69206407T2 (de) Wundverband.
DE69812917T2 (de) Verbände
JP6716841B2 (ja) 止血材
EP1563855B1 (fr) Pansements comprenant du chitosane
CN102850598A (zh) 海藻酸盐-明胶-羧甲基纤维素钠共混膜及其制备和应用
CN110975002A (zh) 一种用于战创伤的止血材料及其制备方法和应用
DE69508356T2 (de) Wundverband
DE60312969T2 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
DE10330960A1 (de) Wirkstoffdotierte absorbierende Polymerteilchen , Zusammensetzung beinhaltend Polykondensatmatrix und absorbierendes Polymer zur Freisetzung einer Wundheilsubstanz
WO2010031862A9 (fr) Utilisation de fibres lyocell et articles contenant des fibres lyocell
CN115475276A (zh) 止血材料及含有其的创伤敷料
EP2011523B1 (fr) Etoffe hémostatique
WO2009098029A2 (fr) Article destiné à panser une plaie
EP2453933B1 (fr) Pansement cutané perméable à la vapeur d'eau
DE202023100113U1 (de) Dreidimensional vernetztes Hydrogel
KR102272285B1 (ko) 수용성 부직포를 기초로 한 피부 부착용 박막 패치

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709200

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09709200

Country of ref document: EP

Kind code of ref document: A2